Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have jointly launched LAB eN², a drug discovery accelerator dedicated to translating academic research into innovative therapeutics for cardiometabolic conditions, rare blood diseases, and rare endocrine disorders. This initiative marks a significant step in bridging the gap between scientific discovery and clinical application, with partnerships established with four US research institutions that will leverage Evotec’s discovery and preclinical platform alongside Novo’s clinical and commercial expertise.
Partnership and Benefits
LAB eN² represents a collaborative effort that will provide participating research institutions with access to Evotec’s cutting-edge discovery and preclinical development platform, as well as the extensive clinical and commercial know-how of Novo Nordisk. This synergy is expected to accelerate the development of novel treatments, potentially transforming the lives of patients suffering from the targeted conditions.
Funding and Development
Through LAB eN², Novo Nordisk will have the option to invest in and develop successful drug candidates emerging from the initiative. This structure not only supports the advancement of academic research but also aligns with Novo Nordisk’s commitment to expanding its pipeline of innovative therapies for unmet medical needs.-Fineline Info & Tech
